For healthcare professionals. Compounded preparations are dispensed on a doctor’s prescription.
Short answer: In a 90-day randomised trial of megaloblastic anaemia, oral cobalamin at 1,000 µg daily for 10 days, then weekly and monthly, produced haematological recovery similar to intramuscular treatment (PMID 14749150). A systematic review of two trials suggests that 2,000 µg daily by mouth may be as effective as intramuscular administration (PMID 16585128). Route and dose remain the prescriber’s decision.
The question and the condition
Cobalamin (vitamin B12) deficiency is, in the words of one randomised trial, “the most common cause of megaloblastic anemia”, and it has been treated with intramuscular cobalamin (Clinical Therapeutics, 2003; PMID 14749150). The same trial notes that some investigators have suggested oral cobalamin treatment may be as effective. A systematic review of trials comparing the two routes observes that most people with vitamin B12 deficiency are treated in primary care with intramuscular vitamin B12 (Family Practice, 2006; PMID 16585128).
The prescriber’s question is therefore whether an oral preparation can replace an injection for a given patient. The records below compare the two routes in adults with megaloblastic anaemia, and in a systematic review of two trials. Neither is a guideline.
The active and the dosing problem
The trials express doses in micrograms (µg) of cobalamin. A prescriber who needs a strength or schedule that a commercial label does not give has to specify it on the prescription. The studies differ in dose, schedule and duration, so no single regimen is set out here.
What the trials show
Randomised trial: oral versus intramuscular cobalamin
This single-centre, prospective, randomised, open-label study, conducted in Turkey, allocated patients aged 16 years or older with megaloblastic anaemia due to cobalamin deficiency to 1,000 µg cobalamin by mouth or intramuscularly, once daily for 10 days, then weekly for four weeks and then monthly (2003; PMID 14749150). Sixty patients completed the study: 26 in the oral group and 34 in the intramuscular group. The abstract reports that all haematological parameters in the oral group changed significantly from day 0 at days 30 and 90, and that “these hematologic parameters and the recovery patterns were similar between the 2 groups” (PMID 14749150). Neurological improvement was detected in 7 of 9 oral-group patients (77.8%) and 9 of 12 intramuscular-group patients (75.0%) at day 30 (PMID 14749150).
Systematic review of two randomised trials
A systematic review of randomised trials comparing oral with intramuscular vitamin B12 identified two trials with 108 participants, and followed up 93 of them from 90 days to four months (2006; PMID 16585128). In one study, the abstract reports that serum vitamin B12 was significantly higher in the oral group than in the intramuscular group at two and four months (PMID 16585128). The review’s conclusion is the basis for the statement in the short answer. Its authors write that the evidence “derived from these limited studies suggests” that 2000 µg doses of oral vitamin B12 daily, and 1000 µg doses initially daily and then weekly and monthly, “may be as effective as intramuscular administration in obtaining short-term haematological and neurological responses” (PMID 16585128).
What these studies leave open
Both are small and older trials, and the review describes its own evidence as coming from limited studies. The trial enrolled adults with megaloblastic anaemia due to cobalamin deficiency, and the cause of deficiency in each patient is what decides whether a route comparison applies. The prescriber’s decision about route depends on that cause, the clinical picture and the monitoring the prescriber plans.
Dosing ranges with sources
| Context | Regimen as reported | Duration as reported | Outcome as reported | PMID |
|---|---|---|---|---|
| Adults with megaloblastic anaemia, oral arm of randomised trial | 1,000 µg by mouth once daily for 10 days, then weekly for four weeks, then monthly | 90-day study | All haematological parameters changed significantly from day 0 at days 30 and 90 | 14749150 |
| Adults with megaloblastic anaemia, intramuscular arm of the same trial | 1,000 µg intramuscularly once daily for 10 days, then weekly for four weeks, then monthly | 90-day study | Recovery patterns similar between the two groups | 14749150 |
| Systematic review of two randomised trials | 2000 µg daily by mouth, or 1000 µg initially daily then weekly and monthly | Not stated in the abstract | May be as effective as intramuscular administration in short-term haematological and neurological responses | 16585128 |
These are regimens reported in the abstracts, not dosing advice for a named patient.
Monitoring reported in the trial
The randomised trial measured haematological parameters on days 0, 10, 30 and 90, and serum vitamin B12 on days 0 and 90 (PMID 14749150). The abstract also records neurological findings across the patients, including sensitive peripheral neuropathy in 9 patients (15.0%), altered cognitive function in 7 patients (11.7%) and loss of vibration sense in 5 patients (8.3%) (PMID 14749150). A prescriber who follows a patient on oral dosing can use the same measures to set the review schedule.
Forms Lynnity prepares for this indication
Vitamin B12 is prepared as a capsule or an oral liquid, to the prescriber’s specification, for one named patient on a registered doctor’s prescription. The microgram strength per unit, the quantity and the schedule are written on the prescription. Good Compounding Practice (GCP) applies to every preparation.
Who the evidence concerns
The randomised trial enrolled adults aged 16 years or older with megaloblastic anaemia from cobalamin deficiency (PMID 14749150). The review’s trials reported short-term responses (PMID 16585128). Neither study addresses every group a Malaysian clinic may see, so the evidence should be applied with that difference in mind.
How to prescribe
Vitamin B12 is prepared only on a registered doctor’s prescription, for one named patient, under Good Compounding Practice (GCP). The prescription must state:
- the active, vitamin B12 (cobalamin), in the form the prescriber specifies;
- the strength per unit in micrograms;
- the form, a capsule or an oral liquid;
- the quantity and the directions, including the loading schedule, the maintenance schedule and the review date.
Send the signed prescription through the contact page at https://www.lynnitypharma.com/contact-us/.
Related reading: nutrient support for patients on GLP-1 therapy and methylated B vitamins and MTHFR. Laboratory standards are described on the GCP laboratory page.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
Frequently asked questions
Is oral vitamin B12 as effective as injection for deficiency anaemia?
The evidence is limited. A 90-day randomised trial reported haematological recovery similar in the oral and intramuscular groups (PMID 14749150). A systematic review of two trials stated that oral dosing may be as effective as intramuscular administration (PMID 16585128). Both are small and older studies, so the choice of route remains the prescriber’s decision for each patient.
What oral dose of vitamin B12 do the trials use?
The randomised trial gave 1,000 µg once daily for 10 days, then weekly for four weeks, then monthly (PMID 14749150). The systematic review’s conclusion refers to 2,000 µg daily by mouth as a dose that may be as effective as intramuscular administration (PMID 16585128). These are study regimens, not dosing advice, and the strength and schedule for an individual patient are set by the prescriber.
What must a vitamin B12 prescription state?
The prescription should state the active and its form, the strength per unit in micrograms, the dosage form (a capsule or an oral liquid), the quantity, and the directions including the loading and maintenance schedule and a review date. The preparation is made for one named patient on a registered doctor’s prescription under Good Compounding Practice (GCP).
Can oral vitamin B12 replace injections in every patient?
No single answer is supported. The cited trials compare oral and intramuscular routes in adults with megaloblastic anaemia from cobalamin deficiency (PMID 14749150), and the review describes its evidence as coming from limited studies (PMID 16585128). The route depends on the cause of deficiency and the clinical picture, which remain the prescriber’s judgement.